MARKET

VKTX

VKTX

Viking Therapeutics Inc
NASDAQ
38.04
+1.05
+2.84%
After Hours: 37.99 -0.05 -0.13% 19:56 06/26 EDT
OPEN
36.36
PREV CLOSE
36.99
HIGH
38.48
LOW
36.13
VOLUME
3.78M
TURNOVER
--
52 WEEK HIGH
43.15
52 WEEK LOW
22.96
MARKET CAP
4.42B
P/E (TTM)
-9.1756
1D
5D
1M
3M
1Y
5Y
1D
Corbus Pharmaceuticals Holdings Inc. Stock Rises 5.9%, Outperforms Peers
Dow Jones · 2d ago
Viking Therapeutics call volume above normal and directionally bullish
TipRanks · 3d ago
Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Bio-Techne (TECH)
TipRanks · 3d ago
Viking Therapeutics on Pace for Highest Close Since November 2025 -- Data Talk
Dow Jones · 3d ago
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN) and Viking Therapeutics (VKTX)
TipRanks · 3d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), AbSci (ABSI) and Viking Therapeutics (VKTX)
TipRanks · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-Broadcom, Micron, Qualcomm
Reuters · 4d ago
Analysts Are Bullish on Top Healthcare Stocks: Silexion Therapeutics (SLXN), Viking Therapeutics (VKTX)
TipRanks · 4d ago
More
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.

Webull offers Viking Therapeutics Inc stock information, including NASDAQ: VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.